Neurocrine Biosciences Announces CEO Succession Plan

Core Points - Neurocrine Biosciences announced the retirement of CEO Kevin Gorman, effective October 11, 2024, with Kyle Gano appointed as CEO-elect [1][2] - Under Dr. Gorman's leadership since 2008, Neurocrine has developed a strong financial position and a mature pipeline, including the successful commercial product INGREZZA® [2][3] - The company has submitted two New Drug Applications for crinecerfont to the FDA for treating classic congenital adrenal hyperplasia [2] - Neurocrine currently has 17 clinical development programs focusing on neurology, neuroendocrinology, and neuropsychology [2] Company Overview - Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company dedicated to developing treatments for under-addressed neurological, neuroendocrine, and neuropsychiatric disorders [6] - The company has a diverse portfolio that includes FDA-approved treatments for tardive dyskinesia and chorea associated with Huntington's disease, as well as a robust pipeline in mid- to late-phase clinical development [6] - INGREZZA is the only once-daily selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved for treating adults with tardive dyskinesia and chorea associated with Huntington's disease [7][8] Leadership Transition - Dr. Gorman expressed confidence in Dr. Gano's ability to lead the company into its next growth phase, highlighting their long-standing collaboration [3] - Dr. Gano has over 23 years of experience at Neurocrine, with a focus on business and corporate development, and has played a key role in the company's strategic collaborations and FDA-approved medicines [4][5] - The Board of Directors is optimistic about Dr. Gano's leadership and vision for the future of Neurocrine [3]